Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Psoralen
Product Details | |
---|---|
Synonyms | Ficusin; Furocoumarin; 6,7-Furanocoumarin; NSC 404562; 7H-Furo[3,2-g]benzopyran-7-one; Furo[3,2-g]coumarin |
Product Type | Chemical |
Properties | |
Formula | C11H6O3 |
MW | 186.16 |
CAS | 66-97-7 |
RTECS | LV0944000 |
Source/Host Chemicals | Isolated from plant source. |
Purity Chemicals | ≥98% (HPLC) |
Appearance | White to off-white powder. |
Solubility | Soluble in DMSO (20mg/ml), DMF (20mg/ml), ethanol (5 mg/ml), ethyl acetate, acetone or water (1mg/ml with warming). |
Identity | Determined by 1H-NMR. |
Declaration | Manufactured by Chemodex. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
InChi Key | ZCCUUQDIBDJBTK-UHFFFAOYSA-N |
Smiles | O=C1C=CC2=C(C=C(OC=C3)C3=C2)O1 |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +20°C |
Long Term Storage | +4°C |
Handling Advice | Protect from light and moisture. |
Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Psoralen is a photoactive probe that has been used to investigate nucleic acid structure and function. It intercalates into DNA and, when activated by ultraviolet radiation, can create covalent interstrand crosslinks, inducing apoptosis. Photosensitizing agent that shows anticancer properties by inducing apoptosis and cell cycle arrest, modulating the Wnt/β-catenin pathway. This compound is also used in molecular biology applications. Because of its high UV absorbance, psoralen has been combined with UVA light (PUVA therapy) for the treatment of skin problems such as psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma. Spectral fluorescence: λex=335nm; λem=460nm (pH 7.0).
(1) K.M. Vasquez; Environ. Mol. Mutagen 51, 527 (2010) | (2) A. Litovchick, et al.; Artif.DNA PNA XNA 5, (2014) | (3) X. Wang, et al.; Biol. Pharm. Bull. 39, 815 (2016) | (4) M. Oldham, et al.; PLoS One 11, e0162078 (2016) | (5) F. Kouzine, et al.; Methods Mol. Biol. 1703, 95 (2018) | (6) X. Wang, et al.; Sci. Rep. 8, 14001 (2018) | (7) J. Guitart; JAMA Dermatol. 155, 529 (2019) |(8) X. Wang, et al.; Biol. Res. 52, 34 (2019)